Because improving glucose control with antidiabetic therapies appears to restore the insulinotropic effect of GIP in patients with T2D, growing evidence suggests that GLP-1R/GIP-R co-agonists could represent a promising strategy for treating T2D and obesity [217]. The gene discussed is GIP; the disease is Obesity.